STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid TumorsNavin Pinto, Julie R. Park, Mallory Taylor et al.|Journal of Clinical Oncology|2024Cited by 46